The Global Coalition on Aging Applauds FDA for New Draft Alzheimer’s Guidance

New guidance provides clarity on endpoints, will help spur pharmaceutical innovation for Alzheimer’s treatments

NEW YORK, NY (17 May 2018) – The Global Coalition on Aging (GCOA) today submitted comments to the U.S. Food & Drug Administration (FDA) supporting the administration’s new regulatory guidance document on early Alzheimer’s disease and calling for similar updates for related dementias. The draft guidance clarifies the clinical endpoints required for early Alzheimer’s disease treatments, reflecting the latest understanding of the disease’s progression, and opening opportunities for increased pharmaceutical innovation.

“By issuing this new draft guidance, the FDA has demonstrated its commitment to rapidly advancing innovation in Alzheimer’s drug development,” said Michael Hodin, CEO of the Global Coalition on Aging. “As Alzheimer’s affects more and more of us across society as the population ages, researchers and regulators alike must adapt based on what the science has taught us. We applaud the FDA for its leadership in recognizing the urgency to update regulations and create a path for faster and smarter processes that remove barriers to innovation.”

GCOA is also calling for the FDA to make advancements in clinical trial enrollment: first, by developing common diagnostic criteria for enrollment in clinical trials. Secondly, GCOA is recommending more aggressive focus on earlier detection and diagnosis to help ensure adequate participation from people with Alzheimer’s in clinical trials. By collecting data earlier in the progression of dementia, researchers can pinpoint drug targets more effectively and efficiently.

GCOA’s comments are in line with findings from the Dementia Innovation Readiness Index,a collaborative report published by GCOA and Alzheimer’s Disease International (ADI) in 2017. It analyzed the readiness of different countries to integrate innovative solutions for dementia treatment, prevention and care into their healthcare and policy systems. In 2017, the Index focused on the G7 countries – Canada, France, Germany, Italy, Japan, and the United Kingdom. In 2018, the Index will expand to focus on select G20 countries – Argentina, Brazil, China, India, and Saudi Arabia. The 2018 edition of the Index will be released at ADI’s annual conference in Chicago this July.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.

Our National Conversation on Aging

Now that President Biden officially declared his run for a second term, what are we to make of the countless warnings about his age? Clearly, voters have already considered age a major factor – Google Search results for ‘Biden age’ hit an all-time-high just before the 2020 election – and speculation has only heightened four years on. Unfortunately, these concerns are misguided and even dangerous because they conflate age with poor health and confuse ideas about work and retirement.

World Immunization Week: Best-Kept Secret for 21st-Century Healthy Aging

The tremendous success of childhood immunisation campaigns across the 20thcentury is one of the greatest triumphs of public health. Along with advances in sanitation and antibiotics, childhood immunisation has resulted in the miracle of modern longevity: the once extravagant prospect of growing old has become the norm. Now, in our 21st century, isn’t it our great challenge to build on this achievement by realising a healthy longevity?

South China Morning Post Letter to the Editor

Antimicrobial resistance is one of the defining global problems of our time. Drug-resistant bacterial infections killed an estimated 1.27 million people in 2019. By 2050, 10 million lives annually could be lost to antimicrobial resistance, and annual global gross domestic product could fall by between 1.1 per cent and 3.8 per cent. Fortunately, Chinese policymakers, physicians and patients have shown what is possible when they focus collective efforts on antimicrobial resistance.

Medicine Price Setting Might Appeal to Voters but Will Cost Patients

As policymakers search for potential cuts to the national budget, they risk jeopardizing the country’s most cost-effective use of healthcare dollars: biomedical innovation regarding vaccines , prescription drugs, and emerging therapies, including antibodies. As the nation rapidly ages, protecting this pipeline of medicine will not only improve health outcomes but will do so at a lower cost by reducing more expensive hospital and primary care.

Global Coalition on Aging Hosts Cross-Sector Roundtable to Tackle Heart Valve Disease in Aging Societies

The Global Coalition on Aging (GCOA) and the Global Heart Hub have released a global position paper “Heart Valve Disease: Harnessing Innovation to Save Lives, Mitigate Costs, and Advance the Healthy Aging Agenda.” The report builds upon on a December 2022 GCOA-GHH roundtable of cross-sector experts and examines how behavior and policy change can best address heart valve disease in our 21st century.

New York City Twins with Ireland to Develop Age Friendly Communities

The twinning commits both sides to share knowledge on age friendly programs and builds on the 2011 Dublin Declaration of Age-Friendly Cities and Communities. The agreement was signed by the Cathaoirleach (Mayor) Nick Killian of Meath County Council which hosts the Irish Age Friendly Programme and Lorraine Cortés-Vázquez, Commissioner for Aging.

Just Getting Started at 75

In the latest charge against the promise of healthy aging, Dr. Ezekiel Emanuel, oncologist and bioethicist, doubled down on his infamous 2014 essay stating that 75 is the ideal age to die. Now 65, he maintains that after age 75, he will no longer receive medical screenings and interventions like colonoscopies, cancer treatment, flu shots, and heart valve replacement.